Claudia Enriquez
Family · Alamogordo, NMNPI 1356985170
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,113 of the $4,314 with a category attached, or 72.2%. 14 manufacturers reported payments, led by Medtronic at 36.8% of the total. 2025 is the largest year on record at $1,755, 2.9 times the $602 reported in 2021. Among family clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 145 payments — averaging $29.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Insulet Corporation$1K
- Xeris Pharmaceuticals, Inc.$536
- AstraZeneca$239
- Mannkind Corporation$219
- Dexcom, Inc.$145
- plus $505 from 8 others
What the payments were for
- Travel & lodging$1,15827%
- Food & beverage$3,11372%
- Education$431%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 20 | $1,587 |
| Insulet Corporation | 56 | $1,083 |
| Xeris Pharmaceuticals, Inc. | 23 | $536 |
| AstraZeneca | 12 | $239 |
| Mannkind Corporation | 9 | $219 |
| Dexcom, Inc. | 6 | $145 |
| Lilly USA, LLC | 5 | $122 |
| Nalu Medical, Inc. | 1 | $112 |
| Novo Nordisk | 4 | $82 |
| Sanofi-aventis U.S. LLC | 4 | $80 |
| Tandem Diabetes Care, Inc. | 2 | $40 |
| Boehringer Ingelheim | 1 | $27 |
| Ascensia Diabetes Care US Inc. | 1 | $24 |
| GRT US Holding, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$1,194
- Nalu Neurostimulation System$112
How this compares
$4,314 in reported general payments places this provider in the 95th percentile of 1,080 family providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 275 | $312,854 |
| OzempicSemaglutide | 192 | $214,027 |
| AfrezzaInsulin Regular, Human | 56 | $199,907 |
| JardianceEmpagliflozin | 189 | $186,726 |
| FarxigaDapagliflozin Propanediol | 93 | $97,442 |
| JanuviaSitagliptin Phosphate | 86 | $91,177 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 56 | $71,696 |
| RybelsusSemaglutide | 45 | $49,251 |
| Tresiba Flextouch U-200Insulin Degludec | 56 | $41,174 |
| TrulicityDulaglutide | 31 | $40,298 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $26,211 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 17 | $25,498 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 17 | $18,836 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 32 | $18,425 |
| Gvoke Hypopen 2-PackGlucagon | 24 | $15,076 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $122 | $363,135369 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $82 | $270,722256 claims |
| Boehringer IngelheimJardiance, Trijardy Xr | $27 | $205,562206 claims |
| Mannkind CorporationAfrezza | $219 | $199,90756 claims |
| AstraZenecaFarxiga | $239 | $97,44293 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,080 family providers in New Mexico.
Other family in Alamogordo
- Alisa SeebergerAlamogordo$4K
- Debra BergstromAlamogordo$4K
- David SeiterFarmington$194K
- Carol HollandRoswell$81K
- Barbara FranklinAlbuquerque$28K
- Laurie CrockettArtesia$19K
- Kaylene CribbsFarmington$17K
- Melanie DuranAlbuquerque$15K
- Irasema LlewellynAlbuquerque$14K
- Jamie LujanLas Cruces$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.